Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07357649
PHASE4

Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.

Official title: Prospective Evaluation of Baricitinib's Effects on Procoagulant State and Atherogenic Index in Rheumatoid Arthritis Patients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2026-01

Completion Date

2026-12

Last Updated

2026-01-22

Healthy Volunteers

Yes

Interventions

DRUG

Baricitinib

Oral baricitinib administered in combination with methotrexate according to standard clinical practice

Locations (1)

Tanta University Hospitals

Tanta, Egypt